All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.

#	Type	Title	Authors	Category	Keywords
372	Poster Presentation	Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase 1 solid tumor trial of AMV564, a novel T-cell engager	Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD;	In-Progress Clinical Trials	Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment
692	Poster Presentation	AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response	Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD;	Novel Single-Agent Immunotherapies	Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy